Grail Stock Soars After Positive FDA Staff Review of Galleri Cancer Test

Grail Inc. (GRAL) shares surged more than 34% after staff reviewers at the U.S. Food and Drug Administration (FDA) released favorable briefing documents for the company's Galleri multi-cancer early detection test. The report, published ahead of a formal advisory committee meeting, provides a significant positive signal for the test's regulatory path.

Favorable Regulatory Signal

The FDA's internal scientists found no major concerns related to the analytical performance, clinical study design, or primary safety profile of the Galleri test, according to the published documents. Galleri is a blood-based screening test, often called a liquid biopsy, designed to detect signals from more than 50 types of cancer in individuals who do not have symptoms.

The positive staff assessment is a critical milestone for investors, as it suggests the agency's own scientists view the clinical evidence as robust. An external panel of advisers is scheduled to convene on Wednesday to formally review Grail's premarket approval application, and the staff's findings will heavily inform that discussion.

Ad

Market Reaction and Analyst Outlook

The news sent Grail's stock up 34.7% in afternoon trading to $108.77, approaching its 52-week high. The rally was amplified by a constructive analyst backdrop, with both UBS and RBC Capital recently initiating coverage on the stock. Both firms highlighted the upcoming advisory committee meeting as a pivotal event and pointed to encouraging performance data from large-scale clinical studies like the PATHFINDER 2 and NHS-Galleri trials.

A broadly positive market also provided a tailwind for the stock. The risk-on sentiment, which saw the Nasdaq Composite gain 2.3% and the S&P 500 rise 1.6%, helped magnify the gains in high-growth biotechnology names like Grail. Developments for Grail are also closely watched by investors in peer companies in the liquid biopsy space, such as Guardant Health and Natera.